Heparin Crisis Leads To New FDA Policy On Consulting Outside Experts
This article was originally published in The Pink Sheet Daily
Executive Summary
A Government Accountability Office report criticizing FDA's retention of outside experts on heparin contamination spurs disclosure and conflict-of-interest screening policies for emergency situations.
You may also be interested in...
Heparin Crisis Spurs Changes In FDA Emergency Response Policies
Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.
Heparin Crisis Spurs Changes In FDA Emergency Response Policies
Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.
Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off
Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.